• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

将血脑屏障肽穿梭体与Fc结构域偶联用于治疗性生物分子的脑内递送。

Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.

作者信息

Cavaco Marco, Frutos Silvia, Oliete Paula, Valle Javier, Andreu David, Castanho Miguel A R B, Vila-Perelló Miquel, Neves Vera

机构信息

Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof Egas Moniz, 1649-028 Lisboa, Portugal.

Proteomics and Protein Chemistry Unit, Department of Experimental and Health Sciences, Pompeu Fabra University, Dr. Aiguader 88, Barcelona Biomedical Research Park, 08003 Barcelona, Spain.

出版信息

ACS Med Chem Lett. 2021 Sep 2;12(11):1663-1668. doi: 10.1021/acsmedchemlett.1c00225. eCollection 2021 Nov 11.

DOI:10.1021/acsmedchemlett.1c00225
PMID:36060671
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9437899/
Abstract

The frequency of brain disease has increased significantly in the past years. After diagnosis, therapeutic options are usually limited, which demands the development of innovative therapeutic strategies. The use of antibody-drug conjugates (ADCs) is promising but highly limited by the existence of the blood-brain barrier (BBB). To overcome the impermeability of this barrier, antibody fragments can be engineered and conjugated to BBB peptide shuttles (BBBpS), which are capable of brain penetration. Herein, we linked the highly efficient BBBpS, PepH3, to the IgG fragment crystallizable (Fc) domain using the streamlined expressed protein ligation (SEPL) method. With this strategy, we obtained an Fc-PepH3 scaffold that can carry different payloads. Fc-PepH3 was shown to be nontoxic, capable of crossing an in vitro cellular BBB model, and able to bind to the neonatal Fc receptor (FcRn), which is responsible for antibody long half-life ( ). Overall, we demonstrated the potential of Fc-PepH3 as a versatile platform readily adaptable to diverse drugs of therapeutic value to treat different brain conditions.

摘要

在过去几年中,脑部疾病的发病率显著上升。诊断后,治疗选择通常有限,这就需要开发创新的治疗策略。抗体药物偶联物(ADC)的应用前景广阔,但由于血脑屏障(BBB)的存在而受到极大限制。为了克服这一屏障的不透性,可以对抗体片段进行工程改造,并与能够穿透大脑的血脑屏障肽穿梭体(BBBpS)偶联。在此,我们使用简化的表达蛋白连接(SEPL)方法,将高效的BBBpS PepH3与免疫球蛋白G(IgG)的可结晶片段(Fc)结构域相连。通过这种策略,我们获得了一种可以携带不同载荷的Fc-PepH3支架。研究表明,Fc-PepH3无毒,能够穿过体外细胞血脑屏障模型,并且能够与负责抗体长半衰期的新生儿Fc受体(FcRn)结合。总体而言,我们证明了Fc-PepH3作为一个通用平台的潜力,它可以很容易地适配各种具有治疗价值的药物,以治疗不同的脑部疾病。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/350e6ba339cf/ml1c00225_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/6c0a424bf95e/ml1c00225_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/0f9d1ccd189c/ml1c00225_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/dc992b1c87cb/ml1c00225_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/350e6ba339cf/ml1c00225_0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/6c0a424bf95e/ml1c00225_0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/0f9d1ccd189c/ml1c00225_0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/dc992b1c87cb/ml1c00225_0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6296/9437899/350e6ba339cf/ml1c00225_0004.jpg

相似文献

1
Conjugation of a Blood Brain Barrier Peptide Shuttle to an Fc Domain for Brain Delivery of Therapeutic Biomolecules.将血脑屏障肽穿梭体与Fc结构域偶联用于治疗性生物分子的脑内递送。
ACS Med Chem Lett. 2021 Sep 2;12(11):1663-1668. doi: 10.1021/acsmedchemlett.1c00225. eCollection 2021 Nov 11.
2
The use of a selective, nontoxic dual-acting peptide for breast cancer patients with brain metastasis.用于脑转移乳腺癌患者的选择性、低毒双作用肽。
Biomed Pharmacother. 2024 May;174:116573. doi: 10.1016/j.biopha.2024.116573. Epub 2024 Apr 12.
3
PepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier.PepH3,一种改良的肽穿梭物,可实现血脑屏障的受体非依赖性转运。
Curr Pharm Des. 2020;26(13):1495-1506. doi: 10.2174/1381612826666200213094556.
4
Targeting Zika Virus with New Brain- and Placenta-Crossing Peptide-Porphyrin Conjugates.用新型可穿越脑和胎盘的肽-卟啉共轭物靶向寨卡病毒
Pharmaceutics. 2022 Mar 29;14(4):738. doi: 10.3390/pharmaceutics14040738.
5
Brain penetrating peptides and peptide-drug conjugates to overcome the blood-brain barrier and target CNS diseases.脑穿透肽和肽药物偶联物克服血脑屏障并靶向中枢神经系统疾病。
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021 Jul;13(4):e1695. doi: 10.1002/wnan.1695. Epub 2021 Jan 20.
6
Fusion of hIgG1-Fc to 111In-anti-amyloid single domain antibody fragment VHH-pa2H prolongs blood residential time in APP/PS1 mice but does not increase brain uptake.将人免疫球蛋白G1(hIgG1)的Fc段与铟-111(111In)标记的抗淀粉样蛋白单域抗体片段VHH-pa2H融合,可延长其在APP/PS1小鼠体内的血液停留时间,但不会增加脑摄取量。
Nucl Med Biol. 2015 Aug;42(8):695-702. doi: 10.1016/j.nucmedbio.2015.03.003. Epub 2015 Mar 18.
7
Branched BBB-shuttle peptides: chemoselective modification of proteins to enhance blood-brain barrier transport.支链血脑屏障穿梭肽:蛋白质的化学选择性修饰以增强血脑屏障转运
Chem Sci. 2018 Sep 18;9(44):8409-8415. doi: 10.1039/c8sc02415d. eCollection 2018 Nov 28.
8
Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation.肽类脑靶向的分子决定因素:实验验证的荟萃分析方法。
Fluids Barriers CNS. 2024 May 27;21(1):45. doi: 10.1186/s12987-024-00545-5.
9
Modifying antibody-FcRn interactions to increase the transport of antibodies through the blood-brain barrier.修饰抗体-FcRn 相互作用以增加抗体通过血脑屏障的转运。
MAbs. 2023 Jan-Dec;15(1):2229098. doi: 10.1080/19420862.2023.2229098.
10
A novel platform for engineering blood-brain barrier-crossing bispecific biologics.一种用于构建穿越血脑屏障的双特异性生物制剂的新型平台。
FASEB J. 2014 Nov;28(11):4764-78. doi: 10.1096/fj.14-253369. Epub 2014 Jul 28.

引用本文的文献

1
Fingolimod synergizes with anti-PD-1 radioimmunotherapy in an experimental multiple sclerosis model through enhanced lymph node retention and CD8 T cell depletion.在实验性多发性硬化症模型中,芬戈莫德通过增强淋巴结滞留和CD8 T细胞耗竭,与抗PD-1放射免疫疗法协同作用。
Front Med (Lausanne). 2025 Jul 3;12:1593933. doi: 10.3389/fmed.2025.1593933. eCollection 2025.
2
Antibody drug conjugates in metastatic brain tumors: current landscape, therapeutic potential and challenges.转移性脑肿瘤中的抗体药物偶联物:现状、治疗潜力与挑战
J Neurooncol. 2025 Jun 5. doi: 10.1007/s11060-025-05083-0.
3
PepH3-modified nanocarriers for delivery of therapeutics across the blood-brain barrier.

本文引用的文献

1
The Challenge of Peptide Proteolytic Stability Studies: Scarce Data, Difficult Readability, and the Need for Harmonization.肽类蛋白稳定性研究的挑战:数据匮乏、可读性差,以及需要协调统一。
Angew Chem Int Ed Engl. 2021 Jan 25;60(4):1686-1688. doi: 10.1002/anie.202006372. Epub 2020 Nov 17.
2
To What Extent Do Fluorophores Bias the Biological Activity of Peptides? A Practical Approach Using Membrane-Active Peptides as Models.荧光团对肽的生物活性有多大影响?以膜活性肽为模型的实用方法。
Front Bioeng Biotechnol. 2020 Sep 9;8:552035. doi: 10.3389/fbioe.2020.552035. eCollection 2020.
3
Streamlined Expressed Protein Ligation: Site-Specific Antibody-Drug Conjugate.
用于跨越血脑屏障递送治疗药物的PepH3修饰纳米载体。
Fluids Barriers CNS. 2025 Apr 1;22(1):31. doi: 10.1186/s12987-025-00641-0.
4
Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation.肽类脑靶向的分子决定因素:实验验证的荟萃分析方法。
Fluids Barriers CNS. 2024 May 27;21(1):45. doi: 10.1186/s12987-024-00545-5.
5
Hopping the Hurdle: Strategies to Enhance the Molecular Delivery to the Brain through the Blood-Brain Barrier.跨越障碍:增强血脑屏障分子传递的策略。
Cells. 2024 May 7;13(10):789. doi: 10.3390/cells13100789.
6
Therapeutic Antibodies in Medicine.医学中的治疗性抗体。
Molecules. 2023 Sep 5;28(18):6438. doi: 10.3390/molecules28186438.
7
Blood-Brain Barrier (BBB)-Crossing Strategies for Improved Treatment of CNS Disorders.血脑屏障(BBB)穿越策略,改善中枢神经系统疾病的治疗。
Handb Exp Pharmacol. 2024;284:213-230. doi: 10.1007/164_2023_689.
8
Enabling the formation of native mAb, Fab' and Fc-conjugates using a bis-disulfide bridging reagent to achieve tunable payload-to-antibody ratios (PARs).使用双二硫键桥接试剂实现天然单克隆抗体、Fab'片段和Fc缀合物的形成,以实现可调节的载药量与抗体比率(PARs)。
Chem Sci. 2023 Mar 9;14(14):3752-3762. doi: 10.1039/d2sc06318b. eCollection 2023 Apr 5.
9
Peptides for trans-blood-brain barrier delivery.穿血脑屏障肽。
J Labelled Comp Radiopharm. 2023 Jul;66(9):237-248. doi: 10.1002/jlcr.4023. Epub 2023 Apr 20.
10
Peptide Shuttles for Blood-Brain Barrier Drug Delivery.用于血脑屏障药物递送的肽穿梭载体
Pharmaceutics. 2022 Sep 5;14(9):1874. doi: 10.3390/pharmaceutics14091874.
蛋白线性化连接:定点抗体药物偶联物。
Methods Mol Biol. 2020;2133:183-200. doi: 10.1007/978-1-0716-0434-2_9.
4
Current approaches to the management of brain metastases.脑转移瘤的治疗方法。
Nat Rev Clin Oncol. 2020 May;17(5):279-299. doi: 10.1038/s41571-019-0320-3. Epub 2020 Feb 20.
5
PepH3, an Improved Peptide Shuttle for Receptor-independent Transport Across the Blood-Brain Barrier.PepH3,一种改良的肽穿梭物,可实现血脑屏障的受体非依赖性转运。
Curr Pharm Des. 2020;26(13):1495-1506. doi: 10.2174/1381612826666200213094556.
6
Antibodies for the Treatment of Brain Metastases, a Dream or a Reality?用于治疗脑转移瘤的抗体,是梦想还是现实?
Pharmaceutics. 2020 Jan 13;12(1):62. doi: 10.3390/pharmaceutics12010062.
7
Immunotherapy of brain metastases: breaking a "dogma".脑转移瘤的免疫治疗:打破“定论”。
J Exp Clin Cancer Res. 2019 Oct 17;38(1):419. doi: 10.1186/s13046-019-1426-2.
8
Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy.优化抗体药物偶联物在癌症治疗中成功构建的挑战
Antibodies (Basel). 2018 Feb 13;7(1):11. doi: 10.3390/antib7010011.
9
Innovative Therapeutic Strategies for Effective Treatment of Brain Metastases.创新治疗策略有效治疗脑转移。
Int J Mol Sci. 2019 Mar 14;20(6):1280. doi: 10.3390/ijms20061280.
10
Antibody-Drug Conjugate-Based Therapeutics: State of the Science.抗体药物偶联物治疗药物:科学现状。
J Natl Cancer Inst. 2019 Jun 1;111(6):538-549. doi: 10.1093/jnci/djz035.